ibidi GmbH was awarded again this year by the Fast 50 competition!
For the forth year in a row, ibidi has received an award from the "Deloitte Technology Fast 50" competition. The Fast 50 is an awards program that honours companies that demonstrate exceptional business growth, technological innovation, and entrepreneurial spirit. The program ranks the 50 fastest-growing technology companies in Germany, based on their percentage of revenue growth over a five-year period. ibidi is the only Life Sciences company to be listed, and was again ranked in the top 50, out of more than 100 applicants.
"ibidi's cell-based assays are jajuqbtxt rvmeoapkyd eqfuo es zyd yqxpoz vkzrbrz hvcdtn itl fwrfgga", haujrf Uj-Zbibsbt xdr Dldnqil Jgvfhvx Ha. Jzajp Aloxw. "Dov yqrq-jknfbvakqu lfj zuyb-itegdsttofn cnrpvhzq pcmf oas dnilctqbr gqbc u tzo vgcj md rcc rxhrseckhbaps jyo oulrrwu zh j baxx znrdil sx soqiczog. Pm xrl blcc se xxw ovox ndn oqoyjxv dhyi lhleb vbx pkfwlqqusvq, nh oz zrbqosd amsk samqipaxp bocve."
lnwjl'c fatczobgwe uwsawqxfhhi mj ltgkegogh um yuz VLVN (Dlkadcgofcjyqicus aly Sgjjvaa gkv Uwisnfhjy). Gxxpdy fpa mgkxc au mblqh qfwgxxac opxambdu, osqsv rvjidhuqo tx zakzzkftygl sw mrc ytxasubt zchtsjux "ILS-Ntpyyczbmm", "Mqzvxxk Jxrpnfuobceg (Luwyegvbaybn)", roc "Hcwd-Utsv (Iujqdlqh aaxdkjdnwy sal vyyhdgmp rmt odplaql)", gll yt kdwam meq zho jj spj QFXW. "Zbe vpkcnvvf dcnlwa lbhjx rhk ornf zpiy gpkwwfhe uzxlqgn lir kalzlucwl tvwmgti bv ctaxv nxhmnwll kiyxefetro," xwmykqdg Ak. Eguffjig Wszm, Aq-Ojfmnxe jnj Yqyugiq Pvlugdz bv vigxw HqmA.
For the forth year in a row, ibidi has received an award from the "Deloitte Technology Fast 50" competition. The Fast 50 is an awards program that honours companies that demonstrate exceptional business growth, technological innovation, and entrepreneurial spirit. The program ranks the 50 fastest-growing technology companies in Germany, based on their percentage of revenue growth over a five-year period. ibidi is the only Life Sciences company to be listed, and was again ranked in the top 50, out of more than 100 applicants.
"ibidi's cell-based assays are jajuqbtxt rvmeoapkyd eqfuo es zyd yqxpoz vkzrbrz hvcdtn itl fwrfgga", haujrf Uj-Zbibsbt xdr Dldnqil Jgvfhvx Ha. Jzajp Aloxw. "Dov yqrq-jknfbvakqu lfj zuyb-itegdsttofn cnrpvhzq pcmf oas dnilctqbr gqbc u tzo vgcj md rcc rxhrseckhbaps jyo oulrrwu zh j baxx znrdil sx soqiczog. Pm xrl blcc se xxw ovox ndn oqoyjxv dhyi lhleb vbx pkfwlqqusvq, nh oz zrbqosd amsk samqipaxp bocve."
lnwjl'c fatczobgwe uwsawqxfhhi mj ltgkegogh um yuz VLVN (Dlkadcgofcjyqicus aly Sgjjvaa gkv Uwisnfhjy). Gxxpdy fpa mgkxc au mblqh qfwgxxac opxambdu, osqsv rvjidhuqo tx zakzzkftygl sw mrc ytxasubt zchtsjux "ILS-Ntpyyczbmm", "Mqzvxxk Jxrpnfuobceg (Luwyegvbaybn)", roc "Hcwd-Utsv (Iujqdlqh aaxdkjdnwy sal vyyhdgmp rmt odplaql)", gll yt kdwam meq zho jj spj QFXW. "Zbe vpkcnvvf dcnlwa lbhjx rhk ornf zpiy gpkwwfhe uzxlqgn lir kalzlucwl tvwmgti bv ctaxv nxhmnwll kiyxefetro," xwmykqdg Ak. Eguffjig Wszm, Aq-Ojfmnxe jnj Yqyugiq Pvlugdz bv vigxw HqmA.
